The introduction of immune checkpoint inhibitors has revolutionized the treatment of lung cancer. However, immunotherapy is highly specific and its success is governed by a number of factors. These include a thorough understanding of the immune evasion mechanism of tumor cells and their microenvironment, and a rigid patient selection procedure. To gain more insights on this topic, join us for an exclusive MasterSeries session titled “ Immunotherapy in Lung Cancer ” with the eminent Oncologist Dr.
Vinayak M on 9 th November , 3:00 PM IST onwards. Stay tuned!
